

Dr. Darshan Shah

Qualifications:

- M.B.B.S. (Dec. 1996) – NHL Municipal Medical College, Ahmedabad
- D.P.M. (Oct. 1998) (1st rank) K.M. School of Post-graduate Medicine and Research, V.S. Hospital, Ahmedabad
- M.D. (Psychiatry) (Nov. 1999) (1st rank) K.M. School of Post-graduate Medicine and Research, V.S. Hospital, Ahmedabad
- Graduate – Psychoanalytic Psychotherapy (2000)
- Special Training in Intensive Short term Dynamic Therapy (ISTDP) – India Core Training – ISTDP Institute, Washington (2015-2017)
- Advanced Core Training – Intensive Short term Dynamic Therapy (ISTDP) – Dynamic Therapy Australia and ISTDP Institute, Washington, USA – 2017-2021
- Training of Trainers – Supervision for ISTDP – ISTDP Institute – 2019 - 2022

Present Status:

- Founder – The Purple Labs – A Mental Health Artificial Intelligence Initiative Startup
- Consultant psychiatrist and psychodynamic psychotherapist – The Purple Centre, Ahmedabad
- Consultant Psychotherapist and Supervisor – Dynamic Therapy, Melbourne
- Intensive short-term dynamic therapy (ISTDP) trainer and Supervisor
- Organizational Behavior and Group Process Facilitator

Experience:

- Convener – Psychotherapy Specialty Section, Indian Psychiatry Society 2023-24
- Co-chairperson – Psychotherapy subcommittee, Indian Psychiatry Society 2020-21
- Convener – Psychotherapy subcommittee, Indian Psychiatry Society 2019-20
- Consultant Psychiatrist – Hope Neurology Care
- Consultant Psychiatrist – HCG Cancer Centre, Ahmedabad
- Visiting faculty – Bopal Physiotherapy College

- Visiting faculty – Khyati Foundation Physiotherapy College
- Consultant Psychiatrist, School Mental Health Services
- Consultant Psychiatrist, Saath Suicide Prevention Center
- Organizational Development and Group process facilitator, Raghudeep Eye Clinic
- Organizational Development and Group process facilitator, Bangladesh Eye Clinic
- Consultant Psychiatrist – Polio Foundation, Ahmedabad
- Research coordinator, The Neurology Centre
- Ex-Assistant Professor of Psychiatry, Pramukhswami Medical College, Karamsad.
- Observership in Hellesdon Hospital, Norwich, U.K.
- Locum Psychiatrist, L. G. General Hospital
- Ex-Psychiatrist – Swami Shantiprakash Hospital and Research Center
- Ex-Psychiatrist – Chipa General Hospital and Welfare Center
- Relationships and Distress Column- Signs of life, The Times of India

Research:

- Numerous paper presentations in Bangalore, New Delhi, Ahmedabad at psychoanalysis conferences.
- Good Clinical Practice training by Quintiles Spectral and Pfizer International Ltd.
- To measure the efficacy and safety of two fixed doses (160 or 320mg/day) of ralfinamide in patients with chronic neuropathic low back pain. A multi-centre, double-blind, randomized, placebo-controlled 12-week study with long term extension. (2008)
- An open label trial to determine the long-term safety of safinamide in Parkinson's disease patients. (2008)
- A randomized, double-blind extension study to assess the long-term safety and to explore the long-term efficacy of zonisamide as monotherapy in newly diagnosed partial seizures. (2008)
- A randomized, multi-centre, double-blind study, to compare the efficacy and safety of zonisamide and carbamazepine as monotherapy in newly diagnosed partial epilepsy. (2008)
- A phase II, randomized, double-blind, placebo controlled, dose response study of the efficacy, safety and tolerability of Fipamezole as an oromucosal fast dissolving tablet in the treatment of Parkinson's disease patients (2008)

- A Randomized, Double-Blind, Parallel-Group, Multi-center Study to Evaluate the Retention Rate, Efficacy, Safety, and Tolerability of Carisbamate, Topiramate and Levetiracetam as Adjunctive Therapy in Subjects with Partial Onset Seizures (Jan 2008)
- A Phase III, double blind, placebo-controlled study to determine the efficacy of a low (50mg/day) and high (100-mg/day) dose range of safinamide, as add-on therapy in patients with idiopathic Parkinson's disease with motor fluctuations treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, and/or an anticholinergic. (Clinirx CRO, Newron pharmaceuticals) (May 2006)
- A Phase III, double blind, placebo-controlled, 12-month extension study to investigate the long-term efficacy and safety of a low (50mg/day) and high (100mg/day) dose range of safinamide, as add-on therapy in patients with idiopathic Parkinson's disease with motor fluctuations treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, and/or an anticholinergic. (Clinirx CRO, Newron pharmaceuticals) (May 2006)
- A Phase II, multicenter, pilot, randomized, ascending dose, double-blind, placebo controlled, dose titration study to determine the safety, maximum tolerated dose and preliminary evidence of efficacy of ralfinamide in the range of 80-320 mg/day in patients with neuropathic pain
- A Phase II twelve week double-blind and placebo-controlled study to evaluate the safety and efficacy of 2 doses of XXXX molecule in subjects with OCD. (Pfizer International)
- A multicenter pilot study to examine the clinical effects of cross titration of Risperidone with ziprasidone in subjects with schizophrenia or schizoaffective disorder followed by an optional open extension phase with continued ziprasidone treatment. (Pfizer International)
- A multicentric assessment of quetiapine fumarate versus Haloperidol in the treatment of schizophrenia – A study of 26 cases. (Sun Pharmaceuticals)
- A randomized, open label study of citalopram; a new antidepressant drug, to evaluate its efficacy and safety in the treatment of mild to moderate depression as compared to fluoxetine – A study of 50 cases. (Torrent Pharmaceuticals)

- A multicenter 10-week randomized double-blind placebo-controlled flexible dose outpatient study of Sertraline in children and adolescents with major depressive disorder. (Pfizer International)
- A study of sociodemographic factors and symptom profile in patients of Major Depressive Disorders – A study of 200 cases. (Pfizer International)
- A clinical study of Post Partum Psychosis – A study of 50 cases.
- Depression in school-going children: An Indian perspective – A study of 1885 subjects.
- A double-blind trial for comparison of efficacy of Risperidone and Haloperidol in 20 schizophrenic patients. (Torrent Pharmaceuticals)
- An open label trial to study the efficacy of Olanzapine in 20 schizophrenic patients.

Professional Memberships:

- Life Member Indian Psychiatric Society
- Life Member Indian Medical Association
- Life Member Gujarat Psychiatry Society
- Affiliate member Indian Psychoanalytic Society

Achievements:

- General Secretary – Smt. N H L Municipal Medical College
- President – Rotaract Club of Ahmedabad-South
- District Editor – District 3050 Rotaract International
- Programmes on All India Radio for Sahay - A programme to help the victims of Gujarat earthquake 2001
- Training seminars for corporates for coping with stress and earthquake related anxieties (Indian Oil Corporation, Themis Pharmaceuticals, Cadila Healthcare)
- Training investigative teams for community work by Unnati (Ahmedabad Community Foundation)
- Parenting workshops
- Training for personality development for various Lions clubs, Rotary clubs, assorted student groups

References:

- Dr. Ajit M Sowani: Neurologist, Zydus Hospitals, Ahmedabad

- Dr. Mahesh Chudgar: M.D. (Psych), D.P.M. (London), Ex Hon. Professor and Head of Department of Psychiatry, Sheth Vadilal Sarabhai Hospital and K.M. School of Post-graduate studies and research center
- Jon Frederickson: MSW, ISTDP Institute, Washington

Contact:

- The Purple Centre - 305, Sigma Icon 2, Opposite Medilink Hospital, Shyamal crossroads, Ahmedabad.
- Mobile No. 9824037887
- E-mail: darshang_1@yahoo.com

1 Jan, 2025